Thomas Jefferson University

Jeffrey Ravetch

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records and Publicatio - Thomas Jefferson University
Address833 Chestnut Street
Philadelphia PA 19023
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    T32GM007718     (RAVETCH, JEFFREY VICTOR)Jul 1, 1978 - Nov 30, 1990
    NIH
    DEVELOPMENTAL GENETICS TRAINING PROGRAM
    Role: Principal Investigator
    R01GM036306     (RAVETCH, JEFFREY VICTOR)Jan 1, 1986 - Mar 31, 1995
    NIH
    IFN-GAMMA ACTIVATION OF MACROPHAGES--INDUCIBLE GENES
    Role: Principal Investigator
    R01GM039256     (RAVETCH, JEFFREY VICTOR)Feb 1, 1988 - Jan 31, 1993
    NIH
    FC RECEPTOR GENES: MACROPHAGES AND LYMPHOCYTES
    Role: Principal Investigator
    R37AI034662     (RAVETCH, JEFFREY VICTOR)Feb 1, 1988 - Jan 31, 2008
    NIH
    Study of Fc Receptor Genes: Macrophages and Lymphocytes
    Role: Principal Investigator
    R01AI034662     (RAVETCH, JEFFREY VICTOR)Feb 1, 1988 - Aug 14, 2013
    NIH
    Study of FcR Genes: Macrophages and Lymphocytes
    Role: Principal Investigator
    R56AI034662     (RAVETCH, JEFFREY VICTOR)Feb 1, 1988 - Jul 31, 2015
    NIH
    Study of FcR Genes: Macrophages and Lymphocytes
    Role: Principal Investigator
    R01AI035119     (RAVETCH, JEFFREY VICTOR)Jan 1, 1994 - Dec 31, 1998
    NIH
    MECHANISMS OF GENETIC VARIATION IN P FALCIPARUM MALARIA
    Role: Principal Investigator
    R01AI035875     (RAVETCH, JEFFREY VICTOR)May 1, 1994 - Jun 30, 2014
    NIH
    FcR Deficient Mice Susceptibility to Pathogens
    Role: Principal Investigator
    R01CA080757     (RAVETCH, JEFFREY VICTOR)Mar 5, 1999 - Mar 31, 2019
    NIH
    Molecular aspects of antitumor antibodies
    Role: Principal Investigator
    R01AI048112     (RAVETCH, JEFFREY VICTOR)Jul 1, 2000 - May 31, 2006
    NIH
    MODULATING AUTOIMMUNE DISEASE BY FC RECEPTORS
    Role: Principal Investigator
    R01AG020192     (RAVETCH, JEFFREY VICTOR)Sep 30, 2001 - Jul 31, 2006
    NIH
    Mechanism of antibody-mediated immunotherapy in AD
    Role: Principal Investigator
    P01AI051573     (RAVETCH, JEFFREY VICTOR)Sep 10, 2002 - Jun 30, 2012
    NIH
    INNATE FUNCTIONS OF DENDRITIC CELLS IN AUTOREACTIVITY
    Role: Principal Investigator
    R21AI053285     (RAVETCH, JEFFREY VICTOR)Sep 30, 2002 - Aug 31, 2004
    NIH
    Novel Strategies for Y pestis Immunotherapy
    Role: Principal Investigator
    P01AI100148     (BJORKMAN, PAMELA J)Feb 10, 2013 - Dec 31, 2028
    NIH
    Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies
    Role: Co-Principal Investigator
    U19AI111825     (RAVETCH, JEFFREY VICTOR)Apr 1, 2014 - Mar 31, 2024
    NIH
    Integrating innate and adaptive pathways in vaccine responses
    Role: Principal Investigator
    R35CA196620     (RAVETCH, JEFFREY VICTOR)Apr 1, 2016 - Aug 31, 2029
    NIH
    Molecular mechanisms of antibody-mediated immunotherapies
    Role: Principal Investigator
    R01AI129795     (RAVETCH, JEFFREY VICTOR)Aug 5, 2017 - Jul 31, 2022
    NIH
    Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir
    Role: Principal Investigator
    R01AI145870     (RAVETCH, JEFFREY VICTOR)Jun 18, 2019 - Jun 30, 2029
    NIH
    Development of vaccination strategies to elicit broadly protective immunity against influenza
    Role: Principal Investigator
    R01AI149297     (SUNDBERG, ERIC JOHN)Apr 8, 2020 - Apr 30, 2030
    NIH
    Engineering IgG-specific endoglycosidases to selectively defeat effector functions
    Role: Co-Principal Investigator
    R01AI153441     (ANTHONY, ROBERT MCCULLOUGH)Jul 1, 2020 - Jun 30, 2025
    NIH
    Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
    Role: Co-Principal Investigator
    R01CA258324     (RAVETCH, JEFFREY VICTOR)May 11, 2021 - Apr 30, 2026
    NIH
    Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sastre DE, Bournazos S, Du J, Boder EJ, Edgar JE, Azzam T, Sultana N, Huliciak M, Flowers M, Yoza L, Xu T, Chernova TA, Ravetch JV, Sundberg EJ. Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies. Cell. 2024 Nov 27; 187(24):6994-7007.e12. PMID: 39437779.
      Citations:    
    2. Osorio JC, Knorr DA, Weitzenfeld P, Yao N, Baez M, DiLillo M, Rahman J, Bromberg J, Postow MA, Ariyan C, Robson ME, Ravetch JV. Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer. Res Sq. 2024 Jun 03. PMID: 38883779.
      Citations:    
    3. Knorr DA, Blanchard L, Leidner RS, Jensen SM, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Marino A, Sprott D, Bifulco CB, Piening B, Dahan R, Osorio JC, Fox BA, Ravetch JV. Fc?RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer Immunol Res. 2024 03 04; 12(3):322-333. PMID: 38147316.
      Citations:    
    4. W?hner M, Brechtelsbauer S, Friedrich N, Vorsatz C, Bulang J, Liang C, Schorr L, Beschin A, Guilliams M, Ravetch J, Nimmerjahn F, Biburger M. Tissue niche occupancy determines the contribution of fetal- versus bone-marrow-derived macrophages to IgG effector functions. Cell Rep. 2024 02 27; 43(2):113757. PMID: 38354088.
      Citations:    
    5. Osorio JC, Smith P, Knorr DA, Ravetch JV. The antitumor activities of anti-CD47 antibodies require Fc-Fc?R interactions. Cancer Cell. 2023 12 11; 41(12):2051-2065.e6. PMID: 37977147.
      Citations:    
    6. Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, Baez M, Fox N, Castro C, Marino AE, Jiang C, Penson A, Hogg SJ, Mi X, Nakajima H, Kunimoto H, Nishimura K, Inoue D, Greenbaum B, Knorr D, Ravetch J, Abdel-Wahab O. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat Cancer. 2023 12; 4(12):1675-1692. PMID: 37872381.
      Citations:    
    7. Edgar JE, Trezise S, Anthony RM, Krammer F, Palese P, Ravetch JV, Bournazos S. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer Fc?R-dependent protection in vivo. Proc Natl Acad Sci U S A. 2023 10 31; 120(44):e2314905120. PMID: 37871218.
      Citations:    
    8. Liu Y, Chen T, Zhu Y, Furey A, Lowary TL, Chan J, Bournazos S, Ravetch JV, Achkar JM. Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan. JCI Insight. 2023 10 23; 8(20). PMID: 37733444.
      Citations:    
    9. Wong JL, Smith P, Angulo-Lozano J, Ranti D, Bochner BH, Sfakianos JP, Horowitz A, Ravetch JV, Knorr DA. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. Proc Natl Acad Sci U S A. 2023 08 29; 120(35):e2306782120. PMID: 37607227.
      Citations:    
    10. Yamin R, Kao KS, MacDonald MR, Cantaert T, Rice CM, Ravetch JV, Bournazos S. Human Fc?RIIIa activation on splenic macrophages drives dengue pathogenesis in mice. Nat Microbiol. 2023 08; 8(8):1468-1479. PMID: 37429907.
      Citations:    
    11. Osorio JC, Smith P, Knorr DA, Ravetch JV. The Antitumor Activities of Anti-CD47 Antibodies Require Fc-Fc?R interactions. bioRxiv. 2023 Jun 29. PMID: 37455857.
      Citations:    
    12. Gupta A, Kao KS, Yamin R, Oren DA, Goldgur Y, Du J, Lollar P, Sundberg EJ, Ravetch JV. Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody. Nat Commun. 2023 05 18; 14(1):2853. PMID: 37202422.
      Citations:    
    13. Wong JL, Smith P, Angulo-Lozano J, Ranti D, Bochner BH, Sfakianos JP, Horowitz A, Ravetch JV, Knorr DA. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. bioRxiv. 2023 Feb 01. PMID: 36778311.
      Citations:    
    14. Gupta A, Kao K, Yamin R, Oren DA, Goldgur Y, Du J, Lollar P, Sundberg EJ, Ravetch JV. Mechanism of glycoform specificity and protection against antibody dependent enhancement by an anti-afucosylated IgG nanobody. bioRxiv. 2023 Jan 24. PMID: 36747840.
      Citations:    
    15. Knorr D, Leidner R, Jensen S, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Sprott D, Bifulco C, Piening B, Dahan R, Fox BA, Ravetch J. FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies. bioRxiv. 2023 Jan 20. PMID: 36711504.
      Citations:    
    16. Kao KS, Gupta A, Zong G, Li C, Kerschbaumer I, Borghi S, Achkar JM, Bournazos S, Wang LX, Ravetch JV. Synthetic nanobodies as tools to distinguish IgG Fc glycoforms. Proc Natl Acad Sci U S A. 2022 11 29; 119(48):e2212658119. PMID: 36409896.
      Citations:    
    17. Sarhan D, Eisinger S, He F, Bergsland M, Pelicano C, Driescher C, Westberg K, Benitez II, Humoud R, Palano G, Li S, Carannante V, Muhr J, ?nfelt B, Schlisio S, Ravetch JV, Heuchel R, L?hr MJ, Karlsson MCI. Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. iScience. 2022 Nov 18; 25(11):105317. PMID: 36310582.
      Citations:    
    18. Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat Immunol. 2022 08; 23(8):1183-1192. PMID: 35902637.
      Citations:    
    19. Gupta A, Smith P, Bournazos S, Ravetch JV. A novel mouse strain optimized for chronic human antibody administration. Proc Natl Acad Sci U S A. 2022 03 08; 119(10):e2123002119. PMID: 35235456.
      Citations:    
    20. Yamin R, Jones AT, Hoffmann HH, Sch?fer A, Kao KS, Francis RL, Sheahan TP, Baric RS, Rice CM, Ravetch JV, Bournazos S. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature. 2021 11; 599(7885):465-470. PMID: 34547765.
      Citations:    
    21. Ou C, Li C, Zhang R, Yang Q, Zong G, Dai Y, Francis RL, Bournazos S, Ravetch JV, Wang LX. One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. Bioconjug Chem. 2021 08 18; 32(8):1888-1897. PMID: 34351736.
      Citations:    
    22. Ibarlucea-Benitez I, Weitzenfeld P, Smith P, Ravetch JV. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2021 06 29; 118(26). PMID: 34155121.
      Citations:    
    23. Bournazos S, Vo HTM, Duong V, Auerswald H, Ly S, Sakuntabhai A, Dussart P, Cantaert T, Ravetch JV. Antibody fucosylation predicts disease severity in secondary dengue infection. Science. 2021 06 04; 372(6546):1102-1105. PMID: 34083490.
      Citations:    
    24. Yamin R, Jones AT, Hoffmann HH, Kao KS, Francis RL, Sheahan TP, Baric RS, Rice CM, Ravetch JV, Bournazos S. Fc-engineered antibody therapeutics with improved efficacy against COVID-19. Res Sq. 2021 May 27. PMID: 34075373.
      Citations:    
    25. Garris CS, Wong JL, Ravetch JV, Knorr DA. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Sci Transl Med. 2021 05 19; 13(594). PMID: 34011627.
      Citations:    
    26. Li C, Chong G, Zong G, Knorr DA, Bournazos S, Aytenfisu AH, Henry GK, Ravetch JV, MacKerell AD, Wang LX. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fc? Receptor Affinity and ADCC Activity. J Am Chem Soc. 2021 05 26; 143(20):7828-7838. PMID: 33977722.
      Citations:    
    27. Sch?fer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Bowen RA, Nussenzweig MC, Sheahan TP. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021 03 01; 218(3). PMID: 33211088.
      Citations:    
    28. Nimmerjahn F, Ravetch JV. Four keys to unlock IgG. J Exp Med. 2021 03 01; 218(3). PMID: 33600555.
      Citations:    
    29. La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G, Mezheyeuski A, Micke P, Ravetch JV, Karlsson MCI, Sarhan D. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. Cancer Res. 2021 02 15; 81(4):956-967. PMID: 33293426.
      Citations:    
    30. Eisinger S, Sarhan D, Boura VF, Ibarlucea-Benitez I, Tyystj?rvi S, Oliynyk G, Arsenian-Henriksson M, Lane D, Wikstr?m SL, Kiessling R, Virgilio T, Gonzalez SF, Kaczynska D, Kanatani S, Daskalaki E, Wheelock CE, Sedimbi S, Chambers BJ, Ravetch JV, Karlsson MCI. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proc Natl Acad Sci U S A. 2020 12 15; 117(50):32005-32016. PMID: 33229588.
      Citations:    
    31. Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Lim SA, Zhou XX, Hobman TC, Kortemme T, Wells JA. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A. 2020 11 10; 117(45):28046-28055. PMID: 33093202.
      Citations:    
    32. Bournazos S, Corti D, Virgin HW, Ravetch JV. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature. 2020 12; 588(7838):485-490. PMID: 33032297.
      Citations:    
    33. Sch?fer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Gazumyan A, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Nussenzweig MC, Sheahan TP. Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo. bioRxiv. 2020 Sep 15. PMID: 32995782.
      Citations:    
    34. Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020 10; 20(10):633-643. PMID: 32782358.
      Citations:    
    35. Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Lim SA, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Zhou XX, Hobman TC, Kortemme T, Wells JA. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. bioRxiv. 2020 Aug 04. PMID: 32766586.
      Citations:    
    36. Borghi S, Bournazos S, Thulin NK, Li C, Gajewski A, Sherwood RW, Zhang S, Harris E, Jagannathan P, Wang LX, Ravetch JV, Wang TT. FcRn, but not Fc?Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci U S A. 2020 06 09; 117(23):12943-12951. PMID: 32461366.
      Citations:    
    37. Van Rompay KKA, Coffey LL, Kapoor T, Gazumyan A, Keesler RI, Jurado A, Peace A, Agudelo M, Watanabe J, Usachenko J, Singapuri A, Immareddy R, Ardeshir A, Stuart JB, Bournazos S, Ravetch JV, Balderes PJ, Lorenz IC, Esswein SR, Keeffe JR, Bjorkman PJ, Wang Q, Rice CM, MacDonald MR, Nussenzweig MC, Robbiani DF. A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. Proc Natl Acad Sci U S A. 2020 04 07; 117(14):7981-7989. PMID: 32209664.
      Citations:    
    38. Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV. Differential requirements for Fc?R engagement by protective antibodies against Ebola virus. Proc Natl Acad Sci U S A. 2019 10 01; 116(40):20054-20062. PMID: 31484758.
      Citations:    
    39. Weitzenfeld P, Bournazos S, Ravetch JV. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. J Clin Invest. 2019 09 03; 129(9):3952-3962. PMID: 31424423.
      Citations:    
    40. Wang TT, Ravetch JV. Functional diversification of IgGs through Fc glycosylation. J Clin Invest. 2019 09 03; 129(9):3492-3498. PMID: 31478910.
      Citations:    
    41. Pradier L, Blanchard-Br?geon V, Bohme A, Debeir T, Menager J, Benoit P, Barneoud P, Taupin V, Bertrand P, Dugay P, Cameron B, Shi Y, Naimi S, Duchesne M, Gagnaire M, Weeden T, Travaline T, Reczek D, Khiroug L, Slaoui M, Brunel P, Fukuyama H, Ravetch J, Canton T, Cohen C. SAR228810: an antibody for protofibrillar amyloid ? peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). Alzheimers Res Ther. 2018 11 28; 10(1):117. PMID: 30486882.
      Citations:    
    42. Knorr DA, Ravetch JV. Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism. Clin Cancer Res. 2019 02 01; 25(3):904-906. PMID: 30397179.
      Citations:    
    43. Giddens JP, Lomino JV, DiLillo DJ, Ravetch JV, Wang LX. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proc Natl Acad Sci U S A. 2018 11 20; 115(47):12023-12027. PMID: 30397147.
      Citations:    
    44. Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci U S A. 2018 11 13; 115(46):E10915-E10924. PMID: 30373815.
      Citations:    
    45. Knorr DA, Dahan R, Ravetch JV. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci U S A. 2018 10 23; 115(43):11048-11053. PMID: 30297432.
      Citations:    
    46. Wang TT, Bournazos S, Ravetch JV. Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. Curr Opin Immunol. 2018 08; 53:124-129. PMID: 29753885.
      Citations:    
    47. Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 2018 03; 14(3):e1006860. PMID: 29505593.
      Citations:    
    48. Casey E, Bournazos S, Mo G, Mondello P, Tan KS, Ravetch JV, Scheinberg DA. A new mouse expressing human Fc? receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia. 2018 02; 32(2):547-549. PMID: 28924242.
      Citations:    
    49. Maamary J, Wang TT, Tan GS, Palese P, Ravetch JV. Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10172-10177. PMID: 28874545.
      Citations:    
    50. Bournazos S, Ravetch JV. Fc? Receptor Function and the Design of Vaccination Strategies. Immunity. 2017 08 15; 47(2):224-233. PMID: 28813656.
      Citations:    
    51. Chen TF, Sazinsky SL, Houde D, DiLillo DJ, Bird J, Li KK, Cheng GT, Qiu H, Engen JR, Ravetch JV, Wittrup KD. Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. J Mol Biol. 2017 08 04; 429(16):2528-2541. PMID: 28694069.
      Citations:    
    52. Bournazos S, Ravetch JV. Diversification of IgG effector functions. Int Immunol. 2017 07 01; 29(7):303-310. PMID: 28472280.
      Citations:    
    53. Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by Antibodies: Recent Progress. Annu Rev Immunol. 2017 04 26; 35:285-311. PMID: 28446061.
      Citations:    
    54. Raz A, Serrano A, Lawson C, Thaker M, Alston T, Bournazos S, Ravetch JV, Fischetti VA. Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis. Proc Natl Acad Sci U S A. 2017 05 02; 114(18):4781-4786. PMID: 28428342.
      Citations:    
    55. Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity. 2017 04 18; 46(4):577-586. PMID: 28410988.
      Citations:    
    56. Lehmann CHK, Baranska A, Heidkamp GF, Heger L, Neubert K, L?hr JJ, Hoffmann A, Reimer KC, Br?ckner C, Beck S, Seeling M, Kie?ling M, Soulat D, Krug AB, Ravetch JV, Leusen JHW, Nimmerjahn F, Dudziak D. DC subset-specific induction of T cell responses upon antigen uptake via Fc? receptors in vivo. J Exp Med. 2017 05 01; 214(5):1509-1528. PMID: 28389502.
      Citations:    
    57. Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017 03 28; 114(13):3485-3490. PMID: 28289219.
      Citations:    
    58. Bournazos S, Ravetch JV. Attenuated Vaccines for Augmented Immunity. Cell Host Microbe. 2017 03 08; 21(3):314-315. PMID: 28279341.
      Citations:    
    59. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R, Ravetch JV. IgG antibodies to dengue enhanced for Fc?RIIIA binding determine disease severity. Science. 2017 01 27; 355(6323):395-398. PMID: 28126818.
      Citations:    
    60. Bournazos S, Ravetch JV. Anti-retroviral antibody Fc?R-mediated effector functions. Immunol Rev. 2017 01; 275(1):285-295. PMID: 28133801.
      Citations:    
    61. Bournazos S, Wang TT, Ravetch JV. The Role and Function of Fc? Receptors on Myeloid Cells. Microbiol Spectr. 2016 12; 4(6). PMID: 28087938.
      Citations:    
    62. Dahan R, Ravetch JV. Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement. Cancer Cell. 2016 09 12; 30(3):369-371. PMID: 27622328.
      Citations:    
    63. Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell. 2016 Jun 16; 165(7):1609-1620. PMID: 27315478.
      Citations:    
    64. Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective Fc?R Engagement. Cancer Cell. 2016 06 13; 29(6):820-831. PMID: 27265505.
      Citations:    
    65. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, ?stling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, Sund M, Brage SE, Fuxe J, Rolny C, Li F, Ravetch JV, Karlsson MC. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep. 2016 05 31; 15(9):2000-11. PMID: 27210762.
      Citations:    
    66. Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A, Ravetch JV, Caskey M, Chakraborty AK, Nussenzweig MC. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science. 2016 May 20; 352(6288):1001-4. PMID: 27199430.
      Citations:    
    67. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016 Feb; 126(2):605-10. PMID: 26731473.
      Citations:    
    68. Bournazos S, Ravetch JV. Fc? receptor pathways during active and passive immunization. Immunol Rev. 2015 Nov; 268(1):88-103. PMID: 26497515.
      Citations:    
    69. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc?Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell. 2015 Oct 12; 28(4):543. PMID: 28854351.
      Citations:    
    70. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc?Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell. 2015 Sep 14; 28(3):285-95. PMID: 26373277.
      Citations:    
    71. Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-Fc?R interactions in IgG-mediated microbial neutralization. J Exp Med. 2015 Aug 24; 212(9):1361-9. PMID: 26282878.
      Citations:    
    72. Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV. Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell. 2015 Jul 02; 162(1):160-9. PMID: 26140596.
      Citations:    
    73. DiLillo DJ, Ravetch JV. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res. 2015 Jul; 3(7):704-13. PMID: 26138698.
      Citations:    
    74. DiLillo DJ, Ravetch JV. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell. 2015 May 21; 161(5):1035-1045. PMID: 25976835.
      Citations:    
    75. Fiebiger BM, Maamary J, Pincetic A, Ravetch JV. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci U S A. 2015 May 05; 112(18):E2385-94. PMID: 25870292.
      Citations:    
    76. Wang TT, Ravetch JV. Immune complexes: not just an innocent bystander in chronic viral infection. Immunity. 2015 Feb 17; 42(2):213-215. PMID: 25692698.
      Citations:    
    77. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014 Sep 11; 158(6):1243-1253. PMID: 25215485.
      Citations:    
    78. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014 Aug 28; 158(5):989-999. PMID: 25131989.
      Citations:    
    79. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014 Aug; 15(8):707-16. PMID: 25045879.
      Citations:    
    80. Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. 2014 Sep 09; 426(18):3166-3179. PMID: 25036289.
      Citations:    
    81. Li F, Smith P, Ravetch JV. Inhibitory Fc? receptor is required for the maintenance of tolerance through distinct mechanisms. J Immunol. 2014 Apr 01; 192(7):3021-8. PMID: 24563255.
      Citations:    
    82. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med. 2014 Feb; 20(2):143-51. PMID: 24412922.
      Citations:    
    83. Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest. 2014 Feb; 124(2):725-9. PMID: 24401277.
      Citations:    
    84. Bournazos S, DiLillo DJ, Ravetch JV. humanized mice to study Fc?R function. Curr Top Microbiol Immunol. 2014; 382:237-48. PMID: 25116103.
      Citations:    
    85. Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential Fc?RIIB coengagement in vivo. Proc Natl Acad Sci U S A. 2013 Nov 26; 110(48):19501-6. PMID: 24218606.
      Citations:    
    86. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc. Proc Natl Acad Sci U S A. 2013 Sep 17; 110(38):E3547. PMID: 24171201.
      Citations:    
    87. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26; 210(9):1695-710. PMID: 23897981.
      Citations:    
    88. Wermeling F, Anthony RM, Brombacher F, Ravetch JV. Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13487-91. PMID: 23898202.
      Citations:    
    89. Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J. Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol. 2013 Aug; 87(15):8535-44. PMID: 23720722.
      Citations:    
    90. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A. 2013 Jun 11; 110(24):9868-72. PMID: 23697368.
      Citations:    
    91. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012 Dec 06; 492(7427):118-22. PMID: 23103874.
      Citations:    
    92. Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A. 2012 Sep 25; 109(39):15859-64. PMID: 23019371.
      Citations:    
    93. Li F, Ravetch JV. A general requirement for Fc?RIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle. 2012 Sep 15; 11(18):3343-4. PMID: 22918247.
      Citations:    
    94. Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc? receptor engagement. Proc Natl Acad Sci U S A. 2012 Jul 03; 109(27):10966-71. PMID: 22723355.
      Citations:    
    95. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun. 2012; 12:13. PMID: 22896758.
      Citations:    
    96. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fc? receptor structural and functional diversity. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):6181-6. PMID: 22474370.
      Citations:    
    97. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci. 2012 Apr; 1253:170-80. PMID: 22288459.
      Citations:    
    98. Mattsson J, Yrlid U, Stensson A, Sch?n K, Karlsson MC, Ravetch JV, Lycke NY. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J Immunol. 2011 Oct 01; 187(7):3641-52. PMID: 21880985.
      Citations:    
    99. Li F, Ravetch JV. Inhibitory Fc? receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011 Aug 19; 333(6045):1030-4. PMID: 21852502.
      Citations:    
    100. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011 Jun 19; 475(7354):110-3. PMID: 21685887.
      Citations:    
    101. Nimmerjahn F, Ravetch JV. Fc?Rs in health and disease. Curr Top Microbiol Immunol. 2011; 350:105-25. PMID: 20680807.
      Citations:    
    102. Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, Smith P, Ravetch JV. Fc?RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A. 2010 Nov 09; 107(45):19396-401. PMID: 20974962.
      Citations:    
    103. Miletic AV, Anzelon-Mills AN, Mills DM, Omori SA, Pedersen IM, Shin DM, Ravetch JV, Bolland S, Morse HC, Rickert RC. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med. 2010 Oct 25; 207(11):2407-20. PMID: 20956547.
      Citations:    
    104. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010 Sep 30; 467(7315):591-5. PMID: 20882016.
      Citations:    
    105. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev. 2010 Jul; 236:265-75. PMID: 20636822.
      Citations:    
    106. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010 May; 30 Suppl 1:S9-14. PMID: 20480216.
      Citations:    
    107. Ravetch J. In vivo veritas: the surprising roles of Fc receptors in immunity. Nat Immunol. 2010 Mar; 11(3):183-5. PMID: 20157296.
      Citations:    
    108. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, Rieben R. Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol. 2009 Dec; 158 Suppl 1:2-13. PMID: 19883419.
      Citations:    
    109. Santiago-Raber ML, Amano H, Amano E, Baudino L, Otani M, Lin Q, Nimmerjahn F, Verbeek JS, Ravetch JV, Takasaki Y, Hirose S, Izui S. Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum. 2009 Aug; 60(8):2408-17. PMID: 19644866.
      Citations:    
    110. Ravetch J. Profile of Jeffrey Ravetch. Interview by Philip Downey. Proc Natl Acad Sci U S A. 2009 May 12; 106(19):7689-91. PMID: 19416845.
      Citations:    
    111. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009 Apr 02; 458(7238):636-40. PMID: 19287373.
      Citations:    
    112. Giorgini A, Brown HJ, Lock HR, Nimmerjahn F, Ravetch JV, Verbeek JS, Sacks SH, Robson MG. Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol. 2008 Dec 15; 181(12):8745-52. PMID: 19050295.
      Citations:    
    113. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009 Jan; 15(1):34-41. PMID: 19079256.
      Citations:    
    114. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20167-72. PMID: 19074274.
      Citations:    
    115. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008 Dec 16; 105(50):19571-8. PMID: 19036920.
      Citations:    
    116. Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol. 2008 Nov 15; 181(10):6829-36. PMID: 18981101.
      Citations:    
    117. Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):15005-9. PMID: 18815375.
      Citations:    
    118. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008 Apr 18; 320(5874):373-6. PMID: 18420934.
      Citations:    
    119. McGaha TL, Karlsson MC, Ravetch JV. FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J Immunol. 2008 Apr 15; 180(8):5670-9. PMID: 18390752.
      Citations:    
    120. Baudino L, Nimmerjahn F, Azeredo da Silveira S, Martinez-Soria E, Saito T, Carroll M, Ravetch JV, Verbeek JS, Izui S. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol. 2008 Feb 01; 180(3):1948-53. PMID: 18209093.
      Citations:    
    121. Ravetch JV. Closing the circle. Jeffrey V. Ravetch, M.D., Ph.D. Interviewed by Lynne Lederman. Biotechniques. 2008 Feb; 44(2):169, 171. PMID: 18330345.
      Citations:    
    122. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008 Jan; 8(1):34-47. PMID: 18064051.
      Citations:    
    123. Nimmerjahn F, Ravetch JV. Analyzing antibody-Fc-receptor interactions. Methods Mol Biol. 2008; 415:151-62. PMID: 18370153.
      Citations:    
    124. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008; 26:513-33. PMID: 18370923.
      Citations:    
    125. Ravetch J, Aderem A. Phagocytic cells. Immunol Rev. 2007 Oct; 219:5-7. PMID: 17850477.
      Citations:    
    126. Nandakumar KS, Collin M, Ols?n A, Nimmerjahn F, Blom AM, Ravetch JV, Holmdahl R. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol. 2007 Oct; 37(10):2973-82. PMID: 17899548.
      Citations:    
    127. Wermeling F, Chen Y, Pikkarainen T, Scheynius A, Winqvist O, Izui S, Ravetch JV, Tryggvason K, Karlsson MC. Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J Exp Med. 2007 Oct 01; 204(10):2259-65. PMID: 17893199.
      Citations:    
    128. Dhodapkar KM, Banerjee D, Connolly J, Kukreja A, Matayeva E, Veri MC, Ravetch JV, Steinman RM, Dhodapkar MV. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med. 2007 Jun 11; 204(6):1359-69. PMID: 17502666.
      Citations:    
    129. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A. 2007 May 15; 104(20):8433-7. PMID: 17485663.
      Citations:    
    130. Ravetch JV, Nussenzweig M. Killing some to make way for others. Nat Immunol. 2007 Apr; 8(4):337-9. PMID: 17375094.
      Citations:    
    131. Kowalewska J, M?hlfeld AS, Hudkins KL, Yeh MM, Farr AG, Ravetch JV, Alpers CE. Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease. Am J Pathol. 2007 Mar; 170(3):981-9. PMID: 17322382.
      Citations:    
    132. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol. 2007 Apr; 19(2):239-45. PMID: 17291742.
      Citations:    
    133. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med. 2007 Jan 22; 204(1):11-5. PMID: 17227911.
      Citations:    
    134. Ehlers M, Ravetch JV. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol. 2007 Feb; 28(2):74-9. PMID: 17197239.
      Citations:    
    135. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol. 2007; 96:179-204. PMID: 17981207.
      Citations:    
    136. Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV, Diamond B. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med. 2006 Sep 04; 203(9):2157-64. PMID: 16923849.
      Citations:    
    137. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006 Aug 04; 313(5787):670-3. PMID: 16888140.
      Citations:    
    138. Maltais LJ, Lovering RC, Taranin AV, Colonna M, Ravetch JV, Dalla-Favera R, Burrows PD, Cooper MD, Davis RS. New nomenclature for Fc receptor-like molecules. Nat Immunol. 2006 May; 7(5):431-2. PMID: 16622424.
      Citations:    
    139. Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Janik J, Brechbiel MW, Waldmann TA. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood. 2006 Jul 15; 108(2):705-10. PMID: 16551968.
      Citations:    
    140. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med. 2006 Mar 20; 203(3):789-97. PMID: 16520389.
      Citations:    
    141. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med. 2006 Mar 20; 203(3):553-61. PMID: 16492804.
      Citations:    
    142. Yamazaki S, Patel M, Harper A, Bonito A, Fukuyama H, Pack M, Tarbell KV, Talmor M, Ravetch JV, Inaba K, Steinman RM. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2758-63. PMID: 16473944.
      Citations:    
    143. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006 Jan; 24(1):19-28. PMID: 16413920.
      Citations:    
    144. Okazaki T, Otaka Y, Wang J, Hiai H, Takai T, Ravetch JV, Honjo T. Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. J Exp Med. 2005 Dec 19; 202(12):1643-8. PMID: 16352741.
      Citations:    
    145. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005 Dec 02; 310(5753):1510-2. PMID: 16322460.
      Citations:    
    146. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest. 2005 Oct; 115(10):2914-23. PMID: 16167082.
      Citations:    
    147. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005 Jul; 23(1):41-51. PMID: 16039578.
      Citations:    
    148. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, Steinman RM, Ravetch JV, Dhodapkar MV. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A. 2005 Feb 22; 102(8):2910-5. PMID: 15703291.
      Citations:    
    149. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science. 2005 Jan 28; 307(5709):590-3. PMID: 15681388.
      Citations:    
    150. Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005 May 01; 105(9):3577-82. PMID: 15665111.
      Citations:    
    151. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol. 2005 Jan; 6(1):99-106. PMID: 15592473.
      Citations:    
    152. Moll T, Nitschke L, Carroll M, Ravetch JV, Izui S. A critical role for Fc gamma RIIB in the induction of rheumatoid factors. J Immunol. 2004 Oct 01; 173(7):4724-8. PMID: 15383609.
      Citations:    
    153. Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW, Carrasquillo JA, Waldmann TA. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res. 2004 Aug 15; 64(16):5825-9. PMID: 15313926.
      Citations:    
    154. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004 Jun 21; 199(12):1659-69. PMID: 15210744.
      Citations:    
    155. Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2004 Mar 15; 103(6):2397-400. PMID: 14630831.
      Citations:    
    156. Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003 Oct 01; 63(19):6453-7. PMID: 14559836.
      Citations:    
    157. M?hlfeld AS, Segerer S, Hudkins K, Carling MD, Wen M, Farr AG, Ravetch JV, Alpers CE. Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am J Pathol. 2003 Sep; 163(3):1127-36. PMID: 12937154.
      Citations:    
    158. Karlsson MC, Guinamard R, Bolland S, Sankala M, Steinman RM, Ravetch JV. Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J Exp Med. 2003 Jul 21; 198(2):333-40. PMID: 12874264.
      Citations:    
    159. Wang C, Khalil M, Ravetch J, Diamond B. The naive B cell repertoire predisposes to antigen-induced systemic lupus erythematosus. J Immunol. 2003 May 01; 170(9):4826-32. PMID: 12707365.
      Citations:    
    160. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 2003 Apr; 18(4):573-81. PMID: 12705859.
      Citations:    
    161. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, Iyoda T, Ravetch J, Dhodapkar M, Inaba K, Nussenzweig M. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci. 2003 Apr; 987:15-25. PMID: 12727620.
      Citations:    
    162. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003 Jul 01; 102(1):284-8. PMID: 12649132.
      Citations:    
    163. Ravetch JV. A full complement of receptors in immune complex diseases. J Clin Invest. 2002 Dec; 110(12):1759-61. PMID: 12488423.
      Citations:    
    164. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res. 2002 Dec 01; 62(23):6891-900. PMID: 12460904.
      Citations:    
    165. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med. 2002 Jun 17; 195(12):1653-9. PMID: 12070293.
      Citations:    
    166. Trcka J, Moroi Y, Clynes RA, Goldberg SM, Bergtold A, Perales MA, Ma M, Ferrone CR, Carroll MC, Ravetch JV, Houghton AN. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity. 2002 Jun; 16(6):861-8. PMID: 12121667.
      Citations:    
    167. Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med. 2002 May 06; 195(9):1167-74. PMID: 11994421.
      Citations:    
    168. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001 Sep 17; 194(6):769-79. PMID: 11560993.
      Citations:    
    169. Khalil M, Inaba K, Steinman R, Ravetch J, Diamond B. T cell studies in a peptide-induced model of systemic lupus erythematosus. J Immunol. 2001 Feb 01; 166(3):1667-74. PMID: 11160209.
      Citations:    
    170. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001 Jan 19; 291(5503):484-6. PMID: 11161202.
      Citations:    
    171. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001; 19:275-90. PMID: 11244038.
      Citations:    
    172. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000 Oct 06; 290(5489):84-9. PMID: 11021804.
      Citations:    
    173. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity. 2000 Aug; 13(2):277-85. PMID: 10981970.
      Citations:    
    174. Guinamard R, Okigaki M, Schlessinger J, Ravetch JV. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol. 2000 Jul; 1(1):31-6. PMID: 10881171.
      Citations:    
    175. Qin D, Wu J, Vora KA, Ravetch JV, Szakal AK, Manser T, Tew JG. Fc gamma receptor IIB on follicular dendritic cells regulates the B cell recall response. J Immunol. 2000 Jun 15; 164(12):6268-75. PMID: 10843680.
      Citations:    
    176. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr; 6(4):443-6. PMID: 10742152.
      Citations:    
    177. Nakamura A, Yuasa T, Ujike A, Ono M, Nukiwa T, Ravetch JV, Takai T. Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med. 2000 Mar 06; 191(5):899-906. PMID: 10704470.
      Citations:    
    178. Fossati-Jimack L, Reininger L, Chicheportiche Y, Clynes R, Ravetch JV, Honjo T, Izui S. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J Exp Med. 1999 Dec 06; 190(11):1689-96. PMID: 10587359.
      Citations:    
    179. Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity. 1999 Jun; 10(6):753-60. PMID: 10403650.
      Citations:    
    180. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, Ravetch JV, Takai T. Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med. 1999 May 17; 189(10):1573-9. PMID: 10330436.
      Citations:    
    181. Guinamard R, Signoret N, Ishiai M, Marsh M, Kurosaki T, Ravetch JV, Masamichi I. B cell antigen receptor engagement inhibits stromal cell-derived factor (SDF)-1alpha chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. J Exp Med. 1999 May 03; 189(9):1461-6. PMID: 10224286.
      Citations:    
    182. Kubagawa H, Chen CC, Ho LH, Shimada TS, Gartland L, Mashburn C, Uehara T, Ravetch JV, Cooper MD. Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B. J Exp Med. 1999 Jan 18; 189(2):309-18. PMID: 9892613.
      Citations:    
    183. Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, Ono M, Ravetch JV, Takai T. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med. 1999 Jan 04; 189(1):187-94. PMID: 9874575.
      Citations:    
    184. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med. 1999 Jan 04; 189(1):179-85. PMID: 9874574.
      Citations:    
    185. Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999; 72:149-77. PMID: 10361574.
      Citations:    
    186. Okada H, Bolland S, Hashimoto A, Kurosaki M, Kabuyama Y, Iino M, Ravetch JV, Kurosaki T. Role of the inositol phosphatase SHIP in B cell receptor-induced Ca2+ oscillatory response. J Immunol. 1998 Nov 15; 161(10):5129-32. PMID: 9820480.
      Citations:    
    187. Suzuki Y, Shirato I, Okumura K, Ravetch JV, Takai T, Tomino Y, Ra C. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. 1998 Oct; 54(4):1166-74. PMID: 9767532.
      Citations:    
    188. Shores EW, Ono M, Kawabe T, Sommers CL, Tran T, Lui K, Udey MC, Ravetch J, Love PE. T cell development in mice lacking all T cell receptor zeta family members (Zeta, eta, and FcepsilonRIgamma). J Exp Med. 1998 Apr 06; 187(7):1093-101. PMID: 9529325.
      Citations:    
    189. Bolland S, Pearse RN, Kurosaki T, Ravetch JV. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity. 1998 Apr; 8(4):509-16. PMID: 9586640.
      Citations:    
    190. Jankovic D, Cheever AW, Kullberg MC, Wynn TA, Yap G, Caspar P, Lewis FA, Clynes R, Ravetch JV, Sher A. CD4+ T cell-mediated granulomatous pathology in schistosomiasis is downregulated by a B cell-dependent mechanism requiring Fc receptor signaling. J Exp Med. 1998 Feb 16; 187(4):619-29. PMID: 9463412.
      Citations:    
    191. Yuan R, Clynes R, Oh J, Ravetch JV, Scharff MD. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J Exp Med. 1998 Feb 16; 187(4):641-8. PMID: 9463414.
      Citations:    
    192. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 1998 Feb 13; 279(5353):1052-4. PMID: 9461440.
      Citations:    
    193. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A. 1998 Jan 20; 95(2):652-6. PMID: 9435247.
      Citations:    
    194. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol. 1998; 16:421-32. PMID: 9597136.
      Citations:    
    195. Vora KA, Ravetch JV, Manser T. Insights into the mechanisms of antibody-affinity maturation and the generation of the memory B-cell compartment using genetically altered mice. Dev Immunol. 1998; 6(3-4):305-16. PMID: 9814604.
      Citations:    
    196. Vora KA, Ravetch JV, Manser T. Amplified follicular immune complex deposition in mice lacking the Fc receptor gamma-chain does not alter maturation of the B cell response. J Immunol. 1997 Sep 01; 159(5):2116-24. PMID: 9278297.
      Citations:    
    197. Ono M, Okada H, Bolland S, Yanagi S, Kurosaki T, Ravetch JV. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell. 1997 Jul 25; 90(2):293-301. PMID: 9244303.
      Citations:    
    198. Miyajima I, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest. 1997 Mar 01; 99(5):901-14. PMID: 9062348.
      Citations:    
    199. Dombrowicz D, Flamand V, Miyajima I, Ravetch JV, Galli SJ, Kinet JP. Absence of Fc epsilonRI alpha chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR beta and gamma chains. J Clin Invest. 1997 Mar 01; 99(5):915-25. PMID: 9062349.
      Citations:    
    200. Vasovic LV, Dyall R, Clynes RA, Ravetch JV, Nikolic-Zugic J. Synergy between an antibody and CD8+ cells in eliminating an established tumor. Eur J Immunol. 1997 Feb; 27(2):374-82. PMID: 9045907.
      Citations:    
    201. Ravetch JV. Fc receptors. Curr Opin Immunol. 1997 Feb; 9(1):121-5. PMID: 9039776.
      Citations:    
    202. Sylvestre D, Clynes R, Ma M, Warren H, Carroll MC, Ravetch JV. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med. 1996 Dec 01; 184(6):2385-92. PMID: 8976192.
      Citations:    
    203. Sylvestre DL, Ravetch JV. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity. 1996 Oct; 5(4):387-90. PMID: 8885871.
      Citations:    
    204. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature. 1996 Sep 19; 383(6597):263-6. PMID: 8805703.
      Citations:    
    205. Seykora JT, Myat MM, Allen LA, Ravetch JV, Aderem A. Molecular determinants of the myristoyl-electrostatic switch of MARCKS. J Biol Chem. 1996 Aug 02; 271(31):18797-802. PMID: 8702537.
      Citations:    
    206. Heiken H, Schulz RJ, Ravetch JV, Reinherz EL, Koyasu S. T lymphocyte development in the absence of Fc epsilon receptor I gamma subunit: analysis of thymic-dependent and independent alpha beta and gamma delta pathways. Eur J Immunol. 1996 Aug; 26(8):1935-43. PMID: 8765042.
      Citations:    
    207. Li M, Wirthmueller U, Ravetch JV. Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice. J Exp Med. 1996 Mar 01; 183(3):1259-63. PMID: 8642269.
      Citations:    
    208. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature. 1996 Jan 25; 379(6563):346-9. PMID: 8552190.
      Citations:    
    209. Economides AN, Ravetch JV, Yancopoulos GD, Stahl N. Designer cytokines: targeting actions to cells of choice. Science. 1995 Nov 24; 270(5240):1351-3. PMID: 7481821.
      Citations:    
    210. Park SY, Arase H, Wakizaka K, Hirayama N, Masaki S, Sato S, Ravetch JV, Saito T. Differential contribution of the FcR gamma chain to the surface expression of the T cell receptor among T cells localized in epithelia: analysis of FcR gamma-deficient mice. Eur J Immunol. 1995 Jul; 25(7):2107-10. PMID: 7621885.
      Citations:    
    211. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995 Jul; 3(1):21-6. PMID: 7621075.
      Citations:    
    212. Rubio JP, Triglia T, Kemp DJ, de Bruin D, Ravetch JV, Cowman AF. A YAC contig map of Plasmodium falciparum chromosome 4: characterization of a DNA amplification between two recently separated isolates. Genomics. 1995 Mar 20; 26(2):192-8. PMID: 7601442.
      Citations:    
    213. Ravetch JV, Margulies DH. Immunology. New tricks for old molecules. Nature. 1994 Nov 24; 372(6504):323-4. PMID: 7969486.
      Citations:    
    214. Ravetch JV. Fc receptors: rubor redux. Cell. 1994 Aug 26; 78(4):553-60. PMID: 8069908.
      Citations:    
    215. Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science. 1994 Aug 19; 265(5175):1095-8. PMID: 8066448.
      Citations:    
    216. Feinman R, Qiu WQ, Pearse RN, Nikolajczyk BS, Sen R, Sheffery M, Ravetch JV. PU.1 and an HLH family member contribute to the myeloid-specific transcription of the Fc gamma RIIIA promoter. EMBO J. 1994 Aug 15; 13(16):3852-60. PMID: 8070412.
      Citations:    
    217. Ravetch JV. Atopy and Fc receptors: mutation is the message? Nat Genet. 1994 Jun; 7(2):117-8. PMID: 7920623.
      Citations:    
    218. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature. 1994 May 26; 369(6478):340. PMID: 8183374.
      Citations:    
    219. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature. 1994 Mar 03; 368(6466):70-3. PMID: 8107887.
      Citations:    
    220. Lanzer M, de Bruin D, Wertheimer SP, Ravetch JV. Organization of chromosomes in Plasmodium falciparum: a model for generating karyotypic diversity. Parasitol Today. 1994 Mar; 10(3):114-7. PMID: 15275494.
      Citations:    
    221. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994 Feb 11; 76(3):519-29. PMID: 8313472.
      Citations:    
    222. de Bruin D, Lanzer M, Ravetch JV. The polymorphic subtelomeric regions of Plasmodium falciparum chromosomes contain arrays of repetitive sequence elements. Proc Natl Acad Sci U S A. 1994 Jan 18; 91(2):619-23. PMID: 8290573.
      Citations:    
    223. Brooks D, Ravetch JV. Fc receptor signaling. Adv Exp Med Biol. 1994; 365:185-95. PMID: 7887303.
      Citations:    
    224. Su Y, Brooks DG, Li L, Lepercq J, Trofatter JA, Ravetch JV, Lebo RV. Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients. Proc Natl Acad Sci U S A. 1993 Nov 15; 90(22):10856-60. PMID: 7504284.
      Citations:    
    225. Sarris AH, Broxmeyer HE, Wirthmueller U, Karasavvas N, Cooper S, Lu L, Krueger J, Ravetch JV. Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J Exp Med. 1993 Sep 01; 178(3):1127-32. PMID: 8350051.
      Citations:    
    226. Lanzer M, Wertheimer SP, de Bruin D, Ravetch JV. Plasmodium: control of gene expression in malaria parasites. Exp Parasitol. 1993 Aug; 77(1):121-8. PMID: 8344402.
      Citations:    
    227. Pearse RN, Feinman R, Shuai K, Darnell JE, Ravetch JV. Interferon gamma-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF3. Proc Natl Acad Sci U S A. 1993 May 01; 90(9):4314-8. PMID: 8483949.
      Citations:    
    228. Salcedo TW, Kurosaki T, Kanakaraj P, Ravetch JV, Perussia B. Physical and functional association of p56lck with Fc gamma RIIIA (CD16) in natural killer cells. J Exp Med. 1993 May 01; 177(5):1475-80. PMID: 8478617.
      Citations:    
    229. Lanzer M, de Bruin D, Ravetch JV. Transcriptional differences in polymorphic and conserved domains of a complete cloned P. falciparum chromosome. Nature. 1993 Feb 18; 361(6413):654-7. PMID: 8437626.
      Citations:    
    230. de Bruin D, Lanzer M, Ravetch JV. Characterization of yeast artificial chromosomes from Plasmodium falciparum: construction of a stable, representative library and cloning of telomeric DNA fragments. Genomics. 1992 Oct; 14(2):332-9. PMID: 1427849.
      Citations:    
    231. Lanzer M, de Bruin D, Ravetch JV. A sequence element associated with the Plasmodium falciparum KAHRP gene is the site of developmentally regulated protein-DNA interactions. Nucleic Acids Res. 1992 Jun 25; 20(12):3051-6. PMID: 1620601.
      Citations:    
    232. Schenkman S, Kurosaki T, Ravetch JV, Nussenzweig V. Evidence for the participation of the Ssp-3 antigen in the invasion of nonphagocytic mammalian cells by Trypanosoma cruzi. J Exp Med. 1992 Jun 01; 175(6):1635-41. PMID: 1534115.
      Citations:    
    233. Lanzer M, de Bruin D, Ravetch JV. Transcription mapping of a 100 kb locus of Plasmodium falciparum identifies an intergenic region in which transcription terminates and reinitiates. EMBO J. 1992 May; 11(5):1949-55. PMID: 1374714.
      Citations:    
    234. Wirthmueller U, Kurosaki T, Murakami MS, Ravetch JV. Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J Exp Med. 1992 May 01; 175(5):1381-90. PMID: 1314888.
      Citations:    
    235. Kurosaki T, Gander I, Wirthmueller U, Ravetch JV. The beta subunit of the Fc epsilon RI is associated with the Fc gamma RIII on mast cells. J Exp Med. 1992 Feb 01; 175(2):447-51. PMID: 1531062.
      Citations:    
    236. Pearse RN, Feinman R, Ravetch JV. Characterization of the promoter of the human gene encoding the high-affinity IgG receptor: transcriptional induction by gamma-interferon is mediated through common DNA response elements. Proc Natl Acad Sci U S A. 1991 Dec 15; 88(24):11305-9. PMID: 1837149.
      Citations:    
    237. Saltiel AR, Ravetch J, Aderem AA. Functional consequences of lipid-mediated protein-membrane interactions. Biochem Pharmacol. 1991 Jun 21; 42(1):1-11. PMID: 1829888.
      Citations:    
    238. Kurosaki T, Gander I, Ravetch JV. A subunit common to an IgG Fc receptor and the T-cell receptor mediates assembly through different interactions. Proc Natl Acad Sci U S A. 1991 May 01; 88(9):3837-41. PMID: 1827205.
      Citations:    
    239. Seykora JT, Ravetch JV, Aderem A. Cloning and molecular characterization of the murine macrophage "68-kDa" protein kinase C substrate and its regulation by bacterial lipopolysaccharide. Proc Natl Acad Sci U S A. 1991 Mar 15; 88(6):2505-9. PMID: 2006186.
      Citations:    
    240. Perussia B, Ravetch JV. Fc gamma RIII (CD16) on human macrophages is a functional product of the Fc gamma RIII-2 gene. Eur J Immunol. 1991 Feb; 21(2):425-9. PMID: 1825635.
      Citations:    
    241. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol. 1991; 9:457-92. PMID: 1910686.
      Citations:    
    242. Pologe LG, de Bruin D, Ravetch JV. A and T homopolymeric stretches mediate a DNA inversion in Plasmodium falciparum which results in loss of gene expression. Mol Cell Biol. 1990 Jun; 10(6):3243-6. PMID: 2188111.
      Citations:    
    243. Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV. Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. Science. 1990 May 11; 248(4956):732-5. PMID: 2139735.
      Citations:    
    244. Kurosaki T, Ravetch JV. A single amino acid in the glycosyl phosphatidylinositol attachment domain determines the membrane topology of Fc gamma RIII. Nature. 1989 Dec 14; 342(6251):805-7. PMID: 2532306.
      Citations:    
    245. Brooks DG, Qiu WQ, Luster AD, Ravetch JV. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med. 1989 Oct 01; 170(4):1369-85. PMID: 2529342.
      Citations:    
    246. Ravetch JV, Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med. 1989 Aug 01; 170(2):481-97. PMID: 2526846.
      Citations:    
    247. Perussia B, Tutt MM, Qiu WQ, Kuziel WA, Tucker PW, Trinchieri G, Bennett M, Ravetch JV, Kumar V. Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene. J Exp Med. 1989 Jul 01; 170(1):73-86. PMID: 2526196.
      Citations:    
    248. Ravetch JV. Chromosomal polymorphisms and gene expression in Plasmodium falciparum. Exp Parasitol. 1989 Jan; 68(1):121-5. PMID: 2645162.
      Citations:    
    249. Pologe LG, Ravetch JV. Large deletions result from breakage and healing of P. falciparum chromosomes. Cell. 1988 Dec 02; 55(5):869-74. PMID: 3056622.
      Citations:    
    250. Luster AD, Weinshank RL, Feinman R, Ravetch JV. Molecular and biochemical characterization of a novel gamma-interferon-inducible protein. J Biol Chem. 1988 Aug 25; 263(24):12036-43. PMID: 3136170.
      Citations:    
    251. Weinshank RL, Luster AD, Ravetch JV. Function and regulation of a murine macrophage-specific IgG Fc receptor, Fc gamma R-alpha. J Exp Med. 1988 Jun 01; 167(6):1909-25. PMID: 2968434.
      Citations:    
    252. Luster AD, Ravetch JV. Genomic characterization of a gamma-interferon-inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol Cell Biol. 1987 Oct; 7(10):3723-31. PMID: 2824996.
      Citations:    
    253. Pologe LG, Pavlovec A, Shio H, Ravetch JV. Primary structure and subcellular localization of the knob-associated histidine-rich protein of Plasmodium falciparum. Proc Natl Acad Sci U S A. 1987 Oct; 84(20):7139-43. PMID: 3313387.
      Citations:    
    254. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med. 1987 Oct 01; 166(4):1084-97. PMID: 2443596.
      Citations:    
    255. Ravetch JV, Luster AD, Weinshank R, Kochan J, Pavlovec A, Portnoy DA, Hulmes J, Pan YC, Unkeless JC. Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science. 1986 Nov 07; 234(4777):718-25. PMID: 2946078.
      Citations:    
    256. Portnoy DA, Erickson AH, Kochan J, Ravetch JV, Unkeless JC. Cloning and characterization of a mouse cysteine proteinase. J Biol Chem. 1986 Nov 05; 261(31):14697-703. PMID: 3533924.
      Citations:    
    257. Pologe LG, Ravetch JV. A chromosomal rearrangement in a P. falciparum histidine-rich protein gene is associated with the knobless phenotype. Nature. 1986 Jul 31-Aug 6; 322(6078):474-7. PMID: 3016553.
      Citations:    
    258. Kochan J, Perkins M, Ravetch JV. A tandemly repeated sequence determines the binding domain for an erythrocyte receptor binding protein of P. falciparum. Cell. 1986 Mar 14; 44(5):689-96. PMID: 3512098.
      Citations:    
    259. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985 Jun 20-26; 315(6021):672-6. PMID: 3925348.
      Citations:    
    260. Ravetch JV, Feder R, Pavlovec A, Blobel G. Primary structure and genomic organization of the histidine-rich protein of the malaria parasite Plasmodium lophurae. Nature. 1984 Dec 13-19; 312(5995):616-20. PMID: 6095114.
      Citations:    
    261. Marks PA, Murate T, Kaneda T, Ravetch J, Rifkind RA. Modulation of gene expression during terminal cell differentiation: murine erythroleukemia. Symp Fundam Cancer Res. 1984; 37:327-40. PMID: 6084863.
      Citations:    
    262. Shin HS, Flaherty L, Artzt K, Bennett D, Ravetch J. Inversion in the H-2 complex of t-haplotypes in mice. Nature. 1983 Nov 24-30; 306(5941):380-3. PMID: 6316154.
      Citations:    
    263. Waldmann TA, Korsmeyer SJ, Hieter PA, Ravetch JV, Broder S, Leder P. Regulation of the humoral immune response: from immunoglobulin genes to regulatory T cell networks. Fed Proc. 1983 May 15; 42(8):2498-503. PMID: 6404657.
      Citations:    
    264. Korsmeyer SJ, Arnold A, Bakhshi A, Ravetch JV, Siebenlist U, Hieter PA, Sharrow SO, LeBien TW, Kersey JH, Poplack DG, Leder P, Waldmann TA. Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest. 1983 Feb; 71(2):301-13. PMID: 6401769.
      Citations:    
    265. Siebenlist U, Ravetch JV, Korsmeyer S, Waldmann T, Leder P. Human immunoglobulin D segments encoded in tandem multigenic families. Nature. 1981 Dec 17; 294(5842):631-5. PMID: 7312051.
      Citations:    
    266. Ravetch JV, Siebenlist U, Korsmeyer S, Waldmann T, Leder P. Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell. 1981 Dec; 27(3 Pt 2):583-91. PMID: 6101209.
      Citations:    
    267. Korsmeyer SJ, Hieter PA, Ravetch JV, Poplack DG, Waldmann TA, Leder P. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci U S A. 1981 Nov; 78(11):7096-100. PMID: 6273911.
      Citations:    
    268. Kirsch IR, Ravetch JV, Kwan SP, Max EE, Ney RL, Leder P. Multiple immunoglobulin switch region homologies outside the heavy chain constant region locus. Nature. 1981 Oct 15-21; 293(5833):585-7. PMID: 6793874.
      Citations:    
    269. Ravetch JV, Kirsch IR, Leder P. Evolutionary approach to the question of immunoglobulin heavy chain switching: evidence from cloned human and mouse genes. Proc Natl Acad Sci U S A. 1980 Nov; 77(11):6734-8. PMID: 6779282.
      Citations:    
    270. Ravetch JV, Horiuchi K, Zinder ND. DNA sequence analysis of the defective interfering particles of bacteriophage f1. J Mol Biol. 1979 Mar 05; 128(3):305-18. PMID: 439137.
      Citations:    
    271. Horiuchi K, Ravetch JV, Zinder ND. DNA replication of bacteriophage f1 in vivo. Cold Spring Harb Symp Quant Biol. 1979; 43 Pt 1:389-99. PMID: 225108.
      Citations:    
    272. Ravetch JV, Horiuchi K, Zinder ND. Nucleotide sequence of the recognition site for the restriction-modification enzyme of Escherichia coli B. Proc Natl Acad Sci U S A. 1978 May; 75(5):2266-70. PMID: 353810.
      Citations:    
    273. Ravetch JV, Horiuchi K, Zinder ND. Nucleotide sequences near the origin of replication of bacteriophage f1. Proc Natl Acad Sci U S A. 1977 Oct; 74(10):4219-22. PMID: 270666.
      Citations:    
    274. Ravetch J, Horiuchi K, Model P. Mapping of bacteriophage f1 ribosome binding sites to their cognate genes. Virology. 1977 Sep; 81(2):341-51. PMID: 331661.
      Citations:    
    275. Ravetch JV, Model P, Robertson HD. Isolation and characterisation of the phiX174 ribosome binding sites. Nature. 1977 Feb 24; 265(5596):698-702. PMID: 859574.
      Citations:    
    276. Ravetch JV, Jakes KS. Intact 3' end of 16S rRNA is not required for specific mRNA binding. Nature. 1976 Jul 08; 262(5564):150-3. PMID: 778638.
      Citations:    
    Ravetch's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (856)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _